Verastem Oncology

Tempus AI and Verastem Oncology have announced a collaboration to develop a companion diagnostic test for the recently FDA-approved combination therapy of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.

Researchers have identified a promising combination therapy using FAK inhibitors with RAF-MEK clamps that effectively overcomes treatment resistance in BRAF V600E-mutated melanoma.

Verastem Oncology will present additional analyses from the Phase 2 RAMP 201 trial evaluating avutometinib plus defactinib in recurrent low-grade serous ovarian cancer at SGO 2025, building on their FDA Priority Review submission.

Verastem Oncology secured a new credit facility of up to $150 million and a $7.5 million equity investment with Oberland Capital, refinancing existing debt with Oxford Finance.

The FDA has granted Priority Review to Verastem Oncology's NDA for avutometinib combined with defactinib for recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC).

Verastem Oncology's RAMP 203 trial evaluates avutometinib and sotorasib with or without defactinib in KRAS G12C mutant non-small cell lung cancer (NSCLC).

Verastem Oncology anticipates a potential FDA decision on avutometinib plus defactinib for recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC) by June 30, 2025.

Verastem Oncology completed its NDA submission for the combination of avutometinib and defactinib to treat recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC).

Verastem Oncology has completed its NDA submission to the FDA for avutometinib plus defactinib to treat recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC).

The FDA has received a rolling NDA for avutometinib plus defactinib to treat recurrent KRAS-mutant low-grade serous ovarian cancer in adults after one prior systemic therapy.